74,00 €
0,03 % heute
L&S, 7. Oktober, 11:23 Uhr
ISIN
US3773221029
Symbol
GKOS
Berichte

Glaukos Corp Aktie News

Neutral
Business Wire
12 Tage alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today celebrated the groundbreaking of its new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama. The new site represents a ma...
Neutral
Business Wire
etwa 2 Monate alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, M...
Positiv
The Motley Fool
2 Monate alt
Glaukos (GKOS -8.55%), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of $124.1 million, beating analyst expectations of $115.5 million by 7.4%.
Neutral
Seeking Alpha
2 Monate alt
Glaukos Corporation (NYSE:GKOS ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Alex R. Thurman - Senior VP & CFO Christopher William Lewis - Vice President of Investor Relations & Corporate Affairs Joseph E.
Neutral
Business Wire
2 Monate alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include: Record net sales of $124.1 million in Q2 2025 increased 30% year-...
Neutral
Business Wire
3 Monate alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The company's management will discuss the results during a c...
Neutral
Business Wire
3 Monate alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-i...
Neutral
Business Wire
3 Monate alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell a...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen